Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Tranylcypromine Sulfate
×
Overview
What is Tranylcypromine Sulfate?
Tranylcypromine sulfate, the active ingredient of tranylcypromine sulfate tablets, is a non-hydrazine MAOI. The chemical name is (±)‑‑2‑phenylcyclopropylamine sulfate (2:1). The molecular formula is (CHN)•HSO and its molecular weight is 364.46. The structural formula is:
Tranylcypromine sulfate tablets film-coated tablets are intended for oral administration. Each round, rose‑red tablet is debossed on one side with the product name “PARNATE” and “SB” and contains tranylcypromine sulfate equivalent to 10 mg of tranylcypromine.
Inactive ingredients consist of microcrystalline cellulose, anhydrous citric acid, croscarmellose sodium, D&C Red No. 7, FD&C Blue No. 2, FD&C Yellow No. 6, gelatin, lactose, magnesium stearate, talc, titanium dioxide, carnauba wax, polyethylene glycol 400 and 8000, and hypromellose.
What does Tranylcypromine Sulfate look like?
What are the available doses of Tranylcypromine Sulfate?
Tablets: 10 mg
What should I talk to my health care provider before I take Tranylcypromine Sulfate?
How should I use Tranylcypromine Sulfate?
Tranylcypromine sulfate tablets are indicated for the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressants. Tranylcypromine sulfate tablets are not indicated for the initial treatment of MDD due to the potential for serious adverse reactions and drug interactions, and the need for dietary restrictions
Tranylcypromine sulfate tablets are for oral use. The recommended dosage is 30 mg per day (in divided doses). If patients do not have an adequate response, increase the dosage in increments of 10 mg per day every 1 to 3 weeks to a maximum 30 mg twice daily (60 mg per day). Dosage increases should be made more gradually in patients at risk for hypotension (e.g., geriatric patients)
What interacts with Tranylcypromine Sulfate?
Sorry No Records found
What are the warnings of Tranylcypromine Sulfate?
Sorry No Records found
What are the precautions of Tranylcypromine Sulfate?
Sorry No Records found
What are the side effects of Tranylcypromine Sulfate?
Sorry No records found
What should I look out for while using Tranylcypromine Sulfate?
Concomitant use or use in rapid succession with other MAOIs; selective serotonin reuptake inhibitors; serotonin and norepinephrine reuptake inhibitors; tricyclic antidepressants; sympathomimetic drugs; and numerous other drugs. See Full Prescribing Information for the full list of contraindicated products (, )
Pheochromocytoma, other catecholamine-releasing paraganglioma ()
Suicidal Thoughts and Behaviors
What might happen if I take too much Tranylcypromine Sulfate?
How should I store and handle Tranylcypromine Sulfate?
Store at 25°C (77° F); excursions permitted to 15-30 °C (59-86°F) [see USP Controlled Room Temperature].Tranylcypromine sulfate tablets (tranylcypromine) tablets are available as: Store between 15° and 30°C (59° and 86°F). Dispense in a tight, light resistant container. Tranylcypromine sulfate tablets (tranylcypromine) tablets are available as: Store between 15° and 30°C (59° and 86°F). Dispense in a tight, light resistant container.
×
Clinical Information
Chemical Structure
No Image found
Clinical Pharmacology
The mechanism of action of tranylcypromine sulfate tablets as an antidepressant is not fully understood, but is presumed to be linked to potentiation of monoamine neurotransmitter activity in the central nervous system (CNS) resulting from its irreversible inhibition of the enzyme monoamine oxidase (MAO).
Non-Clinical Toxicology
Concomitant use or use in rapid succession with other MAOIs; selective serotonin reuptake inhibitors; serotonin and norepinephrine reuptake inhibitors; tricyclic antidepressants; sympathomimetic drugs; and numerous other drugs. See Full Prescribing Information for the full list of contraindicated products (, )
Pheochromocytoma, other catecholamine-releasing paraganglioma ()
Suicidal Thoughts and Behaviors
When given concurrently the following drugs may interact with thiazide diuretics.
In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients. There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied. There were differences in absolute risk of suicidal thoughts and behaviors across the different indications, with the highest incidence in patients with MDD. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1000 patients treated are provided in Table 2.
Table 2: Risk Differences of the Number of Patients of Suicidal Thoughts and Behavior in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric and Adult Patients
It is unknown whether the risk of suicidal thoughts and behaviors in children, adolescents, and young adults extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with MDD that antidepressants delay the recurrence of depression and that depression itself is a risk factor for suicidal thoughts and behaviors.
Monitor all antidepressant-treated patients for any indication for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing tranylcypromine sulfate tablets , in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.
The following adverse reactions are described in greater detail in other sections:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Based on clinical trial data, the most common adverse reactions to tranylcypromine were dry mouth, dizziness, insomnia, sedation, and headache (>30%) and overexcitement, constipation, blurred vision, and tremor (>10%).
The following adverse reactions have been identified in clinical trials or during post approval use of tranylcypromine sulfate tablets:
agranulocytosis, leukopenia, thrombocytopenia, anemia
impaired water excretion compatible with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH)
significant anorexia, weight gain
excessive stimulation/overexcitement, manic symptoms/hypomania, agitation, insomnia, anxiety, confusion, disorientation, loss of libido
dizziness, restlessness/akathisia, akinesia, ataxia, myoclonic jerks, tremor, hyper-reflexia, muscle spasm, paresthesia, numbness, memory loss, sedation, drowsiness, dysgeusia, headaches (without blood pressure elevation)
Eye disorders: blurred vision, nystagmus
tinnitus
tachycardia, palpitations
hypertensive crisis, hypertension, hypotension (including postural hypotension with syncope)
diarrhea, constipation, nausea, abdominal pain, dry mouth, fissuring in corner of mouth
hepatitis, elevated aminotransferases
localized scleroderma, flare-up of cystic acne, urticaria, rash, alopecia, sweating
: urinary retention, urinary incontinence, urinary frequency
: impotence, delayed ejaculation
edema, chills, weakness, fatigue/lethargy
×
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Clonazepam Description
Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake.
Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula:
C15H10ClN3O3 M.W. 315.72
×
Tips
Tips
×
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib).
228 major drug interactions (854 brand and generic names)
210 moderate drug interactions (691 brand and generic names)
2 minor drug interactions (4 brand and generic names)
Show all medications in the database that may interact with Imbruvica (ibrutinib).
